A new single-chain fragment variable (scFv) to TRAIL-R2 receptor produced as minibody (MB2.23) was characterized for anti-lymphoma activity in vivo. For this purpose, a disseminated lymphoma model was generated by intraperitoneal inoculation of BJAB cells in severe combined immunodeficiency mice. Two weekly injections with MB2.23 (10 mg/kg) were able to significantly increase the median survival time of lymphoma bearing animals with respect to the vehicle-treated control mice, providing a rationale for further investigating the use of MB2.23 in anticancer therapy.
In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody / Zauli, G., Corallini, F., Zorzet, S., Grill, V., Marzari, R., Secchiero, P.. - In: INVESTIGATIONAL NEW DRUGS. - ISSN 0167-6997. - STAMPA. - 30(1):(2012), pp. 405-407. [10.1007/s10637-010-9519-y]
In vivo anti-lymphoma activity of an agonistic human recombinant anti-TRAIL-R2 minibody.
ZORZET, SONIA;GRILL, VITTORIO;MARZARI, ROBERTO;
2012-01-01
Abstract
A new single-chain fragment variable (scFv) to TRAIL-R2 receptor produced as minibody (MB2.23) was characterized for anti-lymphoma activity in vivo. For this purpose, a disseminated lymphoma model was generated by intraperitoneal inoculation of BJAB cells in severe combined immunodeficiency mice. Two weekly injections with MB2.23 (10 mg/kg) were able to significantly increase the median survival time of lymphoma bearing animals with respect to the vehicle-treated control mice, providing a rationale for further investigating the use of MB2.23 in anticancer therapy.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
